Why the study?
What are the current options and comparative efficacies of oral antiplatelet strategies in patients undergoing percutaneous coronary intervention?
What are the current options and comparative efficacies of oral antiplatelet strategies in patients undergoing percutaneous coronary intervention?
This review highlights that while newer P2Y12 inhibitors offer superior ischemic protection over clopidogrel in PCI, they are associated with an increased risk of bleeding, emphasizing the need for individualized antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Supports balancing ischemic benefit vs bleeding risk in PCI P2Y12 selection; leaves open optimal individualized strategies for prospective trials.
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y(12) receptor blocker is the standard of care to prevent recurrent ischemic event occurrence in patients undergoing percutaneous intervention. Glycoprotein IIb/IIIa receptor inhibitors are used in addition to DAPT in the highest-risk clinical settings. The persistent occurrence of ischemic events in the presence of DAPT and the irrefutable demonstration of clopidogrel response variability are two potent arguments against the widely practiced nonselective or "one-size-fits-all" strategy of administering clopidogrel therapy and provides a strong rationale for monitoring clopidogrel therapy. New, potent P2Y(12) inhibitors such as prasugrel and ticagrelor are associated with greater platelet inhibition, faster onset of action, and better overall clinical outcomes compared with clopidogrel, but are associated with more non-surgery-related bleeding than clopidogrel. The inhibition of the platelet thrombin receptor may provide additional benefits in attenuating ischemic event occurrence in selected high-risk patients treated with DAPT.
No takes yet. Share an insight, caveat, or question.
Tantry et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: